Prebiotic Blends and Remission in Inflammatory Bowel Disease: A Brazilian Year-Long Nonrandomized Pilot Trial

Background/Objectives: Long-term evidence on microbiome-targeted nutraceuticals in inflammatory bowel disease (IBD) is limited. This exploratory pilot study (feasibility and parameter estimation) described clinical, microbiome, and fecal metabolomic changes during 12 months of supplementation with two regimens. Methods: Single-center, double-blind, nonrandomized, two-arm pilot trial without a placebo arm. Patients with ulcerative colitis (UC) or Crohn’s disease (CD) on stable standard-of-care therapy, all previously using prebiotics, received fructooligosaccharides, galactooligosaccharides, yeast β-glucan, and minerals, alone (Suppl) or with silymarin (Suppl Plus), and were assessed at baseline, 6, and 12 months. The main clinical endpoint, analyzed as exploratory, was remission or mild activity at 12 months (UC, Mayo endoscopic subscore <2; CD, Simple Endoscopic Score for Crohn’s Disease <8); secondary endpoints included fecal calprotectin, C-reactive protein, 16S rRNA gene profiles, and fecal nuclear magnetic resonance metabolomics. Registration (retrospective): Brazilian Registry of Clinical Trials, RBR-7hvd26h. Results: Of 87 participants enrolled, 75 completed follow-up (UC, n=50; CD, n=25); four died. In UC, the proportion in remission or mild activity was 44.0% at baseline and 82.0% at 12 months (p<0.001), and median calprotectin was 406 and 286 µg/g (p=0.046). In CD, the proportion was 88.0% at both time points (p=1.000), without calprotectin change (p=0.968). No difference between arms was detected (UC, p=1.000; CD, p=0.593), with wide confidence intervals. Flatulence increased (2.7% to 16.0%; p=0.009). Genus-level α-diversity increased, and Dorea and Blautia were enriched in UC at 6 months in both differential abundance tools. Fecal xanthine, 4-pyridoxate, and nicotinate signals increased in both diseases (nominal p values). Conclusions: In this nonrandomized pilot without a placebo arm, the changes observed in UC cannot be attributed to supplementation, and the comparison between formulations was underpowered. The findings are hypothesis-generating; a randomized, placebo-controlled trial is ongoing (recruitment completed; RBR-7hvd26h).

Authors

Publication Details

Journal
Biomedicines
Published
2026-11-17
DOI
https://doi.org/10.3390/biomedicines14112664
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Prebiotic Blends and Remission in Inflammatory Bowel Disease: A Brazilian Year-Long Nonrandomized Pilot Trial

Jorge Artur Peçanha de Miranda Coelho, Victor Nehmi Filho, José Pinhata Otoch, Lucas Correia Lins et al.
2 links
Biomedicines
Inflammatory Bowel Disease
article

Prebiotic Blends and Remission in Inflammatory Bowel Disease: A Brazilian Year-Long Nonrandomized Pilot Trial

Jorge Artur Peçanha de Miranda Coelho, Victor Nehmi Filho, José Pinhata Otoch, Lucas Correia Lins, Joyce de Cassia Rosa de Jesus, Junia Elisa Carvalho de Meira, Manoel Alvaro de Freitas Lins Neto
article en

Abstract

Background/Objectives: Long-term evidence on microbiome-targeted nutraceuticals in inflammatory bowel disease (IBD) is limited. This exploratory pilot study (feasibility and parameter estimation) described clinical, microbiome, and fecal metabolomic changes during 12 months of supplementation with two regimens. Methods: Single-center, double-blind, nonrandomized, two-arm pilot trial without a placebo arm. Patients with ulcerative colitis (UC) or Crohn’s disease (CD) on stable standard-of-care therapy, all previously using prebiotics, received fructooligosaccharides, galactooligosaccharides, yeast β-glucan, and minerals, alone (Suppl) or with silymarin (Suppl Plus), and were assessed at baseline, 6, and 12 months. The main clinical endpoint, analyzed as exploratory, was remission or mild activity at 12 months (UC, Mayo endoscopic subscore <2; CD, Simple Endoscopic Score for Crohn’s Disease <8); secondary endpoints included fecal calprotectin, C-reactive protein, 16S rRNA gene profiles, and fecal nuclear magnetic resonance metabolomics. Registration (retrospective): Brazilian Registry of Clinical Trials, RBR-7hvd26h. Results: Of 87 participants enrolled, 75 completed follow-up (UC, n=50; CD, n=25); four died. In UC, the proportion in remission or mild activity was 44.0% at baseline and 82.0% at 12 months (p<0.001), and median calprotectin was 406 and 286 µg/g (p=0.046). In CD, the proportion was 88.0% at both time points (p=1.000), without calprotectin change (p=0.968). No difference between arms was detected (UC, p=1.000; CD, p=0.593), with wide confidence intervals. Flatulence increased (2.7% to 16.0%; p=0.009). Genus-level α-diversity increased, and Dorea and Blautia were enriched in UC at 6 months in both differential abundance tools. Fecal xanthine, 4-pyridoxate, and nicotinate signals increased in both diseases (nominal p values). Conclusions: In this nonrandomized pilot without a placebo arm, the changes observed in UC cannot be attributed to supplementation, and the comparison between formulations was underpowered. The findings are hypothesis-generating; a randomized, placebo-controlled trial is ongoing (recruitment completed; RBR-7hvd26h).

BiomedicinesVol. 14(11)
Good health and well-being
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon